Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Xhance (fluticasone propionate) is a drug-device combination product, which is approved for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xhance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2024
Details:
Xhance (fluticasone propionate) is a glucocorticoid receptor agonist, steroid drug candidate administered via intranasal spray for the treatment of chronic rhinosinusitis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
Xhance (fluticasone propionate) is a drug-device combination product that uses the Exhalation Delivery System designed to deliver a topical anti-inflammatory to the high and deep regions of the nasal cavity where sinuses ventilate and drain.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Xhance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
Xhance is a drug-device combination with fluticasone propionate which is a synthetic trifluorinated corticosteroid which exhibits great binding affinity for the human glucocorticoid receptor and shows anti-inflammatory activity.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Optinose intends to use the net proceeds of the offering for working capital and general corporate purposes, including the commercialization of XHANCE, and the pursuit of a follow-on indication for XHANCE for the treatment of chronic sinusitis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2022
Details:
ReOpen2 was the second of two phase 3 clinical trials in its ReOpen Program which evaluated XHANCE, also referred to as the Exhalation Delivery System with fluticasone (EDS-FLU), as a potential treatment for chronic sinusitis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
XHANCE® (fluticasone propionate) nasal spray is a drug-device combination product combining its proprietary Exhalation Delivery System designed to uniquely deliver drug high and deep in nasal passages with an anti-inflammatory drug.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
The safety profile and tolerability of Fluticasone Propionate in this trial were consistent with its currently labelled safety profile. Adverse events occurring at a rate of more than 3% with XHANCE and common than the Exhalation Delivery System placebo group in this trial.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
XHANCE® (fluticasone propionate), is a drug-device combination product that uses the Exhalation Delivery System met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
Optinose intends to use the net proceeds of the offering for the commercialization of XHANCE, the clinical development of XHANCE for a follow-on indication for the treatment of chronic sinusitis and other potential development programs.
Lead Product(s): Fluticasone Propionate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Xhance
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 18, 2021